This database contains 524 studies, archived under the term: "alzheimer disease"
Click here to filter this large number of results.
Multivariate spatial covariance analysis of 99mTc-exametazime SPECT images in dementia with Lewy bodies and Alzheimer’s disease: utility in differential diagnosis
Colloby, Sean J,
Taylor, John-Paul,
Davison, Christopher M,
Lloyd, Jim J,
Firbank, Michael J,
McKeith, Ian G,
O'Brien, John T
We examined (99m)Tc-exametazime brain blood flow single-photon emission computed tomography (SPECT) images using a spatial covariance analysis (SCA) approach to assess its diagnostic value in distinguishing dementia with Lewy bodies (DLB) from Alzheimer’s disease (AD). Voxel SCA was simultaneously applied to a set of preprocessed images (AD, n=40; DLB, n=26), generating a series of eigenimages […]
Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer’s disease: a multicenter, randomized, open-label, parallel-group study
Choi, Seong Hye,
Park, Kyung Won,
Na, Duk L.,
Han, Hyun Jeong,
Kim, Eun-Joo,
Shim, Yong S.,
Lee, Jae-Hong,
The EXPECT Study Group,
Objective: To compare the tolerability and efficacy of combination therapy of memantine plus rivastigmine patch with rivastigmine patch monotherapy in patients with mild to moderate Alzheimer’s disease (AD).; Research Design and Methods: In this multicenter, randomized, open-label study, patients entered an 8-week run-in period (a 5 cm 2 rivastigmine patch for 4 weeks, then a […]
Women have farther to fall: gender differences between normal elderly and Alzheimer’s disease in verbal memory engender better detection of Alzheimer’s disease in women
Chapman, Robert M.,
Mapstone, Mark,
Gardner, Margaret N.,
Sandoval, Tiffany C.,
McCrary, John W.,
Guillily, Maria D.,
Reilly, Lindsey A.,
DeGrush, Elizabeth
We analyzed verbal episodic memory learning and recall using the Logical Memory (LM) subtest of the Wechsler Memory Scale-III to determine how gender differences in AD compare to those seen in normal elderly and whether or not these differences impact assessment of AD. We administered the LM to both an AD and a Control group, […]
Safety and effectiveness of donepezil on behavioral symptoms in patients with Alzheimer disease
The objective of this study was to evaluate the prevalence and treatment responsiveness of neuropsychiatric symptoms in patients with mild to moderately severe Alzheimer disease recruited in a naturalistic treatment setting in Spain. All the patients, who matched the prescribing recommendations for donepezil and were able to participate in the study, received donepezil (5 to […]
Diagnosis of Alzheimer’s disease patients with rapid cognitive decline in clinical practice: interest of the Deco questionnaire
Carcaillon, L.,
Berrut, G.,
Sellal, F.,
Dartigues, J. F.,
Gillette, S.,
Pere, J. J.,
Bourdeix, I.
Background: Patients with Alzheimer’s disease (AD) who deteriorate rapidly are likely to have a poorer prognosis. There is a clear need for a clinical assessment tool to detect such a decline in newly diagnosed patients.; Objective: To identify the predictive factors of rapid cognitive decline (RCD) in a cohort of patients with mild to moderate […]
Trazodone improves sleep parameters in Alzheimer disease patients: A randomized, double-blind, and placebo-controlled study
Camargos, Einstein F.,
Louzada, Luciana L.,
Quintas, Juliana L.,
Naves, Janeth O.S.,
Louzada, Fernando M.,
Nóbrega, Otávio T.
Objectives: There are no randomized clinical trials regarding efficacy of trazodone in the treatment of sleep disturbances (SD) in patients with Alzheimer disease (AD). We tested the efficacy and safety of trazodone to treat SD in patients with AD. Design: We conducted a double-blind, randomized and controlled trial during periods of 7–9 days at baseline […]
Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
Burstein, Aaron H,
Grimes, Imogene,
Galasko, Douglas R,
Aisen, Paul S,
Sabbagh, Marwan,
Mjalli, Adnan MM
Background: TTP488, an antagonist at the Receptor for Advanced Glycation End products, was evaluated as a potential treatment for patients with mild-to-moderate Alzheimer’s disease (AD). A previous report describes decreased decline in ADAS-cog (delta = 3.1, p = 0.008 at 18 months, ANCOVA with multiple imputation), relative to placebo, following a 5 mg/day dose of TTP488. Acute, reversible cognitive […]
Validation of Alzheimer’s disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer’s Disease Neuroimaging Initiative (E-ADNI)
Buerger, Katharina,
Frisoni, Giovanni,
Uspenskaya, Olga,
Ewers, Michael,
Zetterberg, Henrik,
Geroldi, Cristina,
Binetti, Giuliano,
Johannsen, Peter,
Rossini, Paolo Maria,
Wahlund, Lars-Olof,
Vellas, Bruno,
Blennow, Kaj,
Hampel, Harald
Background: Alzheimer’s Disease Neuroimaging Initiatives (“ADNI”) aim to validate neuroimaging and biochemical markers of Alzheimer’s disease (AD). Data of the pilot European-ADNI (E-ADNI) biological marker programme of cerebrospinal fluid (CSF) and plasma candidate biomarkers are reported.; Methods: Six academic EADC centres recruited 49 subjects (healthy controls, subjects with mild cognitive impairment (MCI) and AD). We […]